Literature DB >> 21652096

Evidence for a role of advanced glycation end products in atrial fibrillation.

Sergio Raposeiras-Roubín1, Bruno K Rodiño-Janeiro, Lilian Grigorian-Shamagian, Ana Seoane-Blanco, María Moure-González, Alfonso Varela-Román, Ezequiel Álvarez, José R González-Juanatey.   

Abstract

BACKGROUND: Recent studies suggested that advanced glycation end-products (AGEs) and their receptor (RAGE) interaction may be promoted by inflammation and oxidative stress. These processes could also contribute to the pathogenesis of atrial fibrillation (AF), but their roles remain poorly defined. We studied the association of AGE-RAGE axis with AF in diabetic and non-diabetic patients, since the axis appears to play a key role in the process.
METHODS: Ninety-seven consecutive outpatients were included in this transversal study. Fifty-nine patients were in sinus rhythm (SR) and 38 in permanent AF. Plasma fluorescent AGEs and soluble RAGE (sRAGE) were measured and comparisons between patients with and without AF were performed. A multivariate logistic regression analysis was made to define the independent factors associated with AF.
RESULTS: Fluorescent AGEs and sRAGE were higher in AF group (74.9 ± 25.6 vs. 61.8 ± 20.1a.u. for fluorescent AGEs, p=0.006; 1714.2 ± 1105.5 vs. 996.1 ± 820.7 pg/mL for sRAGE, p=0.001). These differences were specially marked in non-diabetic patients. Both AGEs and sRAGE directly correlated with left atrial dimensions (r=0.496; r=0.536 for atrial area and r=0.491; r=0.511 for atrial volume, for fluorescent AGEs and sRAGE, respectively, p<0.001). In a multivariate analysis, fluorescent AGEs and sRAGE resulted as markers of AF independent of left atrial distension, diabetes and other confounding variables.
CONCLUSIONS: AGEs and sRAGE plasma levels were higher in patients with AF, independently of diabetes mellitus, and they positively correlated with atrial dimensions, indicating a role for the AGE-RAGE axis in the arrhythmogenic structural atrial remodelling.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21652096     DOI: 10.1016/j.ijcard.2011.05.072

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  17 in total

1.  AGE-RAGE Stress in the Pathophysiology of Atrial Fibrillation and Its Treatment.

Authors:  Kailash Prasad
Journal:  Int J Angiol       Date:  2019-12-09

Review 2.  Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.

Authors:  Remi Neviere; Yichi Yu; Lei Wang; Frederic Tessier; Eric Boulanger
Journal:  Glycoconj J       Date:  2016-06-08       Impact factor: 2.916

Review 3.  Catheter ablation in atrial fibrillation: is there a mortality benefit in patients with diabetes and heart failure?

Authors:  M Matta; A Saglietto; P De Salvo; A Bissolino; A Ballatore; M Anselmino
Journal:  Herz       Date:  2019-05       Impact factor: 1.443

4.  HbA1c levels as predictors of ablation outcome in type 2 diabetes mellitus and paroxysmal atrial fibrillation.

Authors:  Z-H Lu; N Liu; R Bai; Y Yao; S-N Li; R-H Yu; C-H Sang; R-B Tang; D-Y Long; X Du; J-Z Dong; C-S Ma
Journal:  Herz       Date:  2014-10-23       Impact factor: 1.443

5.  sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Mahmoud Al Rifai; Andrea L C Schneider; Alvaro Alonso; Nisa Maruthur; Christina M Parrinello; Brad C Astor; Ron C Hoogeveen; Elsayed Z Soliman; Lin Y Chen; Christie M Ballantyne; Marc K Halushka; Elizabeth Selvin
Journal:  J Diabetes Complications       Date:  2014-11-25       Impact factor: 2.852

Review 6.  Oxidant and Inflammatory Mechanisms and Targeted Therapy in Atrial Fibrillation: An Update.

Authors:  Alejandra Gutierrez; David R Van Wagoner
Journal:  J Cardiovasc Pharmacol       Date:  2015-12       Impact factor: 3.105

Review 7.  Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies.

Authors:  Ting-Wei Lee; Ting-I Lee; Yung-Kuo Lin; Yao-Chang Chen; Yu-Hsun Kao; Yi-Jen Chen
Journal:  Cell Mol Life Sci       Date:  2020-09-23       Impact factor: 9.261

8.  Advanced glycation end products predict long-term outcome of catheter ablation in paroxysmal atrial fibrillation.

Authors:  Allan Bohm; Lubos Urban; Lubomira Tothova; Ljuba Bacharova; Peter Musil; Jan Kyselovic; Peter Michalek; Tomas Uher; Branislav Bezak; Peter Olejnik; Robert Hatala
Journal:  J Interv Card Electrophysiol       Date:  2021-03-10       Impact factor: 1.900

9.  Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression.

Authors:  Yuji Ishibashi; Takanori Matsui; Seiji Ueda; Kei Fukami; Sho-ichi Yamagishi
Journal:  Cardiovasc Diabetol       Date:  2014-03-13       Impact factor: 9.951

Review 10.  Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes.

Authors:  Basil S Karam; Alejandro Chavez-Moreno; Wonjoon Koh; Joseph G Akar; Fadi G Akar
Journal:  Cardiovasc Diabetol       Date:  2017-09-29       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.